Glancy Prongay Wolke & Rotter LLP has launched a securities fraud investigation into Capricor Therapeutics, Inc. following the release of FDA briefing documents that raised concerns about the company's cell therapy deramiocel. The FDA stated that Capricor's method of converting raw change to percent change and back was not scientifically justified, adding complexity and reducing accuracy, and concluded that the benefit-risk assessment for deramiocel appears unfavorable without evidence of effectiveness. Cantor Fitzgerald analyst Kristen Kluska described the briefing documents as painting an ugly picture and raising concerns about data integrity. On July 27, 2026, Capricor shares fell $12.70, or 64.5%, to close at $7.00, and then declined a further $0.42, or 6.08%, to $6.57 on July 29, 2026, after an FDA advisory committee meeting. The law firm is urging investors who suffered losses to contact them about potentially pursuing claims.
Capricor Therapeutics IncFDA briefing documents raised concerns about deramiocel's efficacy and data integrity, leading to a 64.5% stock drop.